USPTO serial 97916626
MERCALIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 12, 2025
- Examiner
- STEEL, ALYSSA PALADINO
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MERCALIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
MORRISVILLE, NC
MORRISVILLE, NC
MORRISVILLE, NC
Morrisville, NC
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Larry L. Coats
Larry L. Coats COATS & BENNETT, PLLC1400 CRESCENT GREENSUITE 300CARY, NC 27518Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business management and administration of pharmacy reimbursement programs; Managing and administering the distribution of prescription pharmaceutical samples to physicians and patients for pharmaceutical manufacturers; Business management and administration of patient co-pay reimbursement programs on behalf of pharmaceutical manufacturers; Business management and administration of financial assistance programs that provide patients with access to affordable medicine, namely business management and administration of enrollment and reimbursement programs for the purchase of medication and generally facilitating access to medications; Business management and administration of patient support programs for pharmaceutical manufacturers; Business management and administration of patient engagement programs for pharmaceutical manufacturers; Business management and administration of formulary, patient, and payer policy information for pharmaceutical, medical device, and diagnostic manufacturers; Business management and administration of educational engagements for Health Care Providers, namely, business management and administration of efforts to educate healthcare providers on medications, disease status and standard of care; Management of the distribution of clinical trial medication and supplies on behalf of pharmaceutical manufacturers; Providing business marketing information, namely, tracking pharmaceutical promotional programs for pharmaceutical manufacturers and evaluating and determining their effectiveness; Data management services in the field of pharmaceutical patient safety, namely, collecting adverse product events data, storing the data, and reporting collected adverse product events data; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, promoting awareness of diseases, pharmaceutical brands, and treatment affordable options; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, marketing services in the nature of promotion of pharmaceutical manufacturers and disease treatment options via social media; Business information services, namely, tracking payer coverage policies and related documentation and providing life sciences clients access to such in order to enhance their market access strategies and patient support programs; Life science business strategy consulting services for assisting clients with commercial assessments, corporate and portfolio strategy, new product planning and commercialization support, and pricing and market access insights; Business assistance services, namely, enrolling patients of pharmaceutical manufacturers into support programs that enable patients to view, track, and manage the support program wherein the patient support program provides pharmaceutical consumer product information, payer coverage status updates, and providing business information regarding access to enrollment and reimbursement programs for the purchase of medications; Providing business information and news to the pharmaceutical and life sciences industries on legislative and regulatory developments as it impacts and relates to the pharmaceutical and life sciences industries within the copay or patient affordability space | ACTIVE | Sep 20, 2023 |
| 036 | Payment services, namely, reimbursement payment processing in the field of pharmaceutical financial assistance programs and loyalty program payment processing services provided on behalf of pharmaceutical manufacturers for the purpose of delivering benefits to patients enrolled in pharmaceutical manufacturer-sponsored financial assistance programs; Pharmacy benefit manager (PBM) accumulator mitigation services and detecting claim activity indicative of a pharmacy benefit manager attempting to abuse the use of co-pay cards by not applying amounts paid by clients towards the patient's deductible or annual out-of-pocket expense; Anti-kickback and risk mitigation services for the pharmaceutical industry, namely, antikickback compliance services for assuring that patients who have full or partial federally funded drug coverage are excluded from utilizing co-pay cards | ACTIVE | Sep 20, 2023 |
| 041 | Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, providing podcasts, seminars, workshops, and virtual and in-person presentations for educational purposes in the field of diseases, pharmaceutical brands, and affordable healthcare options | ACTIVE | Sep 20, 2023 |
| 042 | Quality assurance and quality control patient claim services for monitoring paid claims to patients from insurance or pharmaceutical entities to insure that specific business rules are being correctly applied to patient claims; Pharmacovigilance services for others, namely, scientific research and analysis pertaining to adverse events and product quality complaints regarding pharmaceutical products, assessment of risks presented by certain pharmaceutical products or combinations thereof, and product safety testing and consultation related thereto in the field of pharmaceuticals; Pharmacovigilance services for others, namely, monitoring the quality of efficacy of pharmaceutical preparations; Providing online non-downloadable software for patient support services, namely, for enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, clinical support services including injection and product educational training, access to financial assistance programs, payer coverage status updates, patient engagement services and reminders and notifications | ACTIVE | Sep 20, 2023 |
| 045 | Pharmacy benefit fraud monitoring, namely, investigation services related to pharmacy benefit insurance claims | ACTIVE | Sep 20, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MERCALIS INC.
- Other trademarks owned by MERCALIS INC.
- Other trademarks owned by MERCALIS INC.
- Other trademarks owned by TrialCard Incorporated
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named MERCALIS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 12, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 12, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 23, 2025 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jul 23, 2025 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jul 18, 2025 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jul 16, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 3, 2025 | IUAF | USE AMENDMENT FILED | — |
| Apr 3, 2025 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Oct 8, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 13, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 13, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 24, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 11, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 10, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 10, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 10, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 5, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 5, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 5, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 3, 2024 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 15, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 14, 2024 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| May 1, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 1, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 1, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 1, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 1, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 25, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 25, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 25, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 29, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 29, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 29, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 29, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 15, 2023 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| May 31, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 5, 2023 | NWAP | NEW APPLICATION ENTERED | — |